Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 4/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 10/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 6/20 | 0.31 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17675432 | 0.86 | LRRK2 (0.33) | GRM2LRRK2BACE1CTSD | |
| SCHEMBL17675444 | 0.81 | BACE1 (0.37) | ACHEGRM1PRMT5WDR77BACE1 | |
| SCHEMBL17675455 | 0.71 | GRM2 (0.36) | GRM2MAOAACHELRRK2PRMT5 | |
| SCHEMBL17675553 | 0.66 | BACE1 (0.35) | LRRK2PRMT5WDR77BACE1CTSD | |
| SCHEMBL17675652 | 0.66 | BACE1 (0.51) | BACE1BACE2CTSD | |
| SCHEMBL446547 | 0.62 | BACE1 (0.49) | BACE1BACE2CTSD | |
| SCHEMBL30285494 | 0.59 | PARP10 (0.54) | — | |
| SCHEMBL17675689 | 0.59 | BACE1 (0.39) | BACE1BACE2CTSD | |
| SCHEMBL8023234 | 0.57 | MAOA (0.48) | MAOAPRMT5WDR77BACE1CTSD | |
| SCHEMBL17675273 | 0.57 | TDP2 (0.36) | ACHEPRMT5WDR77BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10053453-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2018-08-21 | — | — | US | disclosed |
| US-20170313686-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313686-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313686-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2017-11-02 | — | — | US | disclosed |
| WO-2016055858-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016055858-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313686-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | BACE1, BACE2, APP | GRM2 2147/4885MAOA 68/4885ACHE 30/4885 |
| US-10053453-B2 | Compounds and their use as BACE inhibitors | BACE1, BACE2, APP | GRM2 2147/4885MAOA 68/4885ACHE 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.